SCHEMBL3608913

SCHEMBL3608913

CC(C)(C)c1ccc(-c2csc(NC(=N)N)n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR4 P51679 1/20 0.55
MAPT P10636 3/20 0.51
NPSR1 Q6W5P4 2/20 0.48
TDP1 Q9NUW8 2/20 0.48
HK1 P19367 1/20 0.48
HKDC1 Q2TB90 1/20 0.48
KDM4C Q9H3R0 1/20 0.48
GSTO1 P78417 2/20 0.47
MRE11 P49959 2/20 0.47
ALDH1A1 P00352 2/20 0.47
LMNA P02545 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
ABL1 P00519 2/20 0.47
KDM4E B2RXH2 1/20 0.47
KMT2A Q03164 1/20 0.47
TRPA1 O75762 1/20 0.46
USP2 O75604 1/20 0.44
AMY1A P0DUB6 1/20 0.44
GAA P10253 1/20 0.44
THRB P10828 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3599413 0.86 GSTO1 (0.63) MAPTNPSR1GSTO1MRE11KDM4E
SCHEMBL4330728 0.86 ADORA3 (0.48) CCR4MAPTNPSR1TDP1GSTO1
SCHEMBL4334954 0.85 MAPT (0.52) CCR4MAPTALDH1A1LMNASMN1; SMN2
SCHEMBL3603727 0.84 GSTO1 (0.60) MAPTNPSR1TDP1GSTO1ALDH1A1
SCHEMBL3604799 0.82 ALOX5 (0.61) MAPTNPSR1TDP1GSTO1ALDH1A1
SCHEMBL3594785 0.82 MAPT (0.65) MAPTNPSR1TDP1ALDH1A1LMNA
SCHEMBL3607468 0.82 ABL1 (0.51) MAPTNPSR1TDP1GSTO1MRE11
SCHEMBL3598628 0.81 MAPT (0.58) MAPTGSTO1ALDH1A1LMNASMN1; SMN2
SCHEMBL3610890 0.81 MAPT (0.64) MAPTNPSR1TDP1ALDH1A1LMNA
SCHEMBL30660071 0.81 MAPT (0.48) MAPTNPSR1TDP1GSTO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US claimed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN claimed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP claimed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO claimed
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies ASTRAZENECA AB (SE) 2010-11-25 US disclosed
CN-101466692-A Thiazol-guanidine derivatives useful as a (beta) - related pathologies ASTRAZENECA AB (SE) 2009-06-24 CN disclosed
EP-2010508-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES AstraZeneca AB (SE) 2009-01-07 EP disclosed
WO-2007120096-A1 THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES ASTRAZENECA AB (SE) 2007-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298340-A1 Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies GRN, MAPT, GUCY1B1 CCR4 4652/4885MAPT 2/4885NPSR1 3395/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.